Celebration, Fla-based KemPharm Inc, a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, recently updated its prodrug development pipeline. KemPharm is investigating “KP1077” as a potential treatment for idiopathic hypersomnia (IH), a sleep disorder of excessive sleepiness.
Travis C. Mickle, PhD, president and CEO of KemPharm, says in a release, “We continue to expand our pipeline with new growth opportunities for the company. In this regard, we are pleased to announce the discovery of our newest prodrug candidate, KP1077.”
It leverages KemPharm’s proprietary LAT (ligand activated therapy) technology, which the company utilizes to generate improved prodrug versions of US Food and Drug Administration (FDA)-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
Mickle adds that KP1077 may qualify for both Fast-Track status and Orphan Drug designation from the FDA.